Ignite Creation Date:
2024-05-06 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 2:27 PM
Study NCT ID:
NCT05276973
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2022-03-11
Brief Title:
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment Paclitaxel and Carboplatin for Stage III or IV Epithelial Ovarian Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Fallopian Tube Endometrioid Adenocarcinoma |
| Fallopian Tube High Grade Serous Adenocarcinoma |
| Ovarian Endometrioid Adenocarcinoma |
| Ovarian High Grade Serous Adenocarcinoma |
| Primary Peritoneal Endometrioid Adenocarcinoma |
| Primary Peritoneal High Grade Serous Adenocarcinoma |
| Stage III Fallopian Tube Cancer AJCC v8 |
| Stage III Ovarian Cancer AJCC v8 |
| Stage III Primary Peritoneal Cancer AJCC v8 |
| Stage IV Fallopian Tube Cancer AJCC v8 |
| Stage IV Ovarian Cancer AJCC v8 |
| Stage IV Primary Peritoneal Cancer AJCC v8 |
| Unresectable Fallopian Tube Endometrioid Adenocarcinoma |
| Unresectable Fallopian Tube High Grade Serous Adenocarcinoma |
| Unresectable Ovarian Endometrioid Adenocarcinoma |
| Unresectable Ovarian High Grade Serous Adenocarcinoma |
| Unresectable Primary Peritoneal Endometrioid Adenocarcinoma |
| Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma |
Keywords: